BRAF and melanoma: Since the Hungarian oncological protocols usually incorporate the results of novel discoveries, target- and immunotherapeutic agents were also introduced into the treatment of melanoma: the BRAF inhibitor vemurafenib was officially registered in 2012, and the CTLA4 inhibitor ipilimumab was accepted in 2011, while the PD1 inhibitors nivolumab and pembrolizumab were accepted in 2015.